Project Grant R01HL174909
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$723K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
The federal Project Grant award of $428,220.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the University of Colorado-Denver to provide innovative insights into the progression of pulmonary hypertension. The research aims to unravel the role of localized small extracellular vesicles, with the performance period running from Dec 1, 2024 to Nov 30, 2026. This award demonstrates the university's significant...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to better understand changes in the pulmonary vasculature and their relationship to lung disease in patients with pulmonary hypertension and chronic obstructive pulmonary disease (COPD). The $812,189 award, effective May 1, 2025 through February 28, 2029, will leverage data from several NIH-funded cohorts, including...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the eicosanoid-degrading enzyme 15-PGDH in cardiac fibrosis and heart failure. The $558,291 award to the University of Colorado-Denver will fund three specific aims to test the hypothesis that inhibiting 15-PGDH can prevent and reverse the activation of cardiac fibroblasts, which...
This $539,264 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of the carboxylesterase 1 (CES1) enzyme in the development and progression of pulmonary arterial hypertension (PAH). The research aims to: 1) determine how loss of CES1 leads to metabolic changes and lipotoxicity in pulmonary microvascular endothelial cells (PMVECs), 2) evaluate if loss of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $126,059 to the University of Colorado-Denver to explore the systems biology of acute and chronic multi-organ failure in children with congenital heart disease (CHD). The award aims to use "omics" technologies and high-dimensional data analysis to identify novel biomarkers and molecular pathways associated with...
This federal Project Grant award (R00HL165026) from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $498,000.00 in funding to the University of Florida to investigate the role of microglia and neuroinflammation in the pathophysiology of pulmonary hypertension. The key objectives are to: Evaluate the microglia-dependent mechanisms that contribute to increased preautonomic neuron activity in the paraventricular nucleus of the hypothalamus....
This federal Project Grant award of $5,715,866.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop novel, transformative therapies to substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The award, with a performance period from September 2024 to July 2029, will fund four projects and three cores to re-shape the understanding of PF natural history by investigating the...
This $764,891 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research at Baylor College of Medicine to define new regulatory mechanisms governing vascular remodeling in pulmonary hypertension associated with interstitial lung disease (ILD-PH). The primary objectives are to: Characterize the transcriptional regulation of the BMPER gene, which encodes a secreted protein that regulates vascular development, during...
This Project Grant award, valued at $131,783 and awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research study focused on identifying blood and lung fluid biomarkers for phenotypes and acute exacerbations of chronic obstructive pulmonary disease (COPD). The study protocol will enroll COPD patients undergoing bronchoscopic lung volume reduction procedures, as well as stable subjects with and without...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $658,885 to the University of Missouri System to conduct research on targeting the Response Gene to Complement 32 (RGC-32) to alleviate vascular remodeling in pulmonary arterial hypertension (PAH). The key objectives are to determine the molecular mechanisms by which RGC-32 regulates the endothelial-mesenchymal transition (EnDoMT)...